Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-α-producing antigen-presenting cells

Arthritis and Rheumatism

Volumn 58, Issue 3, 2008, Pages 801-812

  Yan, Bing ^a   Ye, Shuang ^a,b   Chen, Guangjie ^b   Kuang, Miao ^c   Shen, Nan ^a   Chen, Shunle ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI UNIVERSITY OF MEDICINE AND HEALTH SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LUCIFERASE; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ADULT; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DNA RESPONSIVE ELEMENT; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REMISSION; SUPERNATANT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD4; CASE-CONTROL STUDIES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RNA, MESSENGER; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 40549128298     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23268     Document Type: Article

References (37)

1. + regulatory T cells in immunological tolerance to self and non-self [review]. Nat Immunol 2005;6:345-52.
2. Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 2006;212:217-37.
3. + T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis. J Immunol 2005;175:944-50.
4. Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand black/New Zealand white lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 2006;177:1451-9.
5. + regulatory T cells generated ex vivo with IL-2 and TGF-β suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 2004;172:1531-9.
6. Chen Y, Cuda C, Morel L. Genetic determination of T cell help in loss of tolerance to nuclear antigens. J Immunol 2005;174:7692-702.
7. Monk CR, Spachidou M, Rovis F, Leung E, Botto M, Lechler RI, et al. MRL/Mp CD4+,CD25- T cells show reduced sensitivity to suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum 2005;52:1180-4.
8. Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol 2007;178:271-9.
9. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21:273-6.
10. + T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004;59:198-202.
11. high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006;65:1512-7.
12. Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006;27:110-8.
13. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005;175:8392-400.
14. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007;178:2579-88.
15. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
17. Oberg HH, Wesch D, Lenke J, Kabelitz D. An optimized method for the functional analysis of human regulatory T cells. Scand J Immunol 2006;64:353-60.
18. Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-7.
19. high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
20. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
21. + T reg cells. J Exp Med 2006;203:1701-11.
22. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-700.
23. Lee JH, Wang LC, Lin YT, Yang YH, Lin DT, Chiang BL. Inverse correlation between CD4+ regulatory T-cell population and auto-antibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006;117:280-6.
24. + T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
25. hi T-regulatory cells. Blood 2006;108:253-61.
26. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;18:676-82.
27. Bonelli M, von Dalwigk K, Savitskaya A, Smolen JS, Scheinecker C. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus (SLE): a comparative phenotypic analysis. Ann Rheum Dis 2007. E-pub ahead of print.
28. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007;123:18-29.
29. - T cells. J Clin Invest 2003;112:1437-43.
30. Banham AH, Powrie FM, Suri-Payer E. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur J Immunol 2006;36:2832-6.
31. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006;25:383-92.
32. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001;294:1540-3.
33. Nacionales DC, Kelly KM, Lee PY, Zhuang H, Li Y, Weinstein JS, et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol 2006;168:1227-40.
34. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9.
35. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006;107:3229-34.
36. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005;202:1575-85.
37. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115:407-17.